Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-014 in advanced prostate cancer
NCT06795178Phase 3Withdrawn
- Sponsor
- Foresee Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of FP-014 in prostate cancer (PCa), sponsored by Foresee Pharmaceuticals. Primary endpoint: Percentage of patients with serum testosterone < 50 ng/dL at Day 28. Planned start Jul 2025; status: withdrawn.
02
Drugs
FP-014
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06795178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795178.